21P Stock Chart & Stats
€2.37
-€0.01(-0.42%)
At close: 4:00 PM EDT
€2.37
-€0.01(-0.42%)
Day’s Range― - ―
52-Week Range€2.22 - €5.62
Previous CloseN/A
Volume86.00
Average Volume (3M)4.48K
Market Cap
€162.64M
Enterprise Value€117.20
Total Cash (Recent Filing)€149.12M
Total Debt (Recent Filing)€22.68M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 11, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding64,861,820
10 Day Avg. Volume3,589
30 Day Avg. Volume4,484
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.64Price Target Upside53.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€178.27M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And LiquidityNearly $150M of cash and no debt provides durable financial flexibility: it reduces refinancing risk, funds working capital and capex while the business repairs profitability, and allows opportunistic M&A or investments without near-term capital markets dependence.
International Revenue Growth And Market LeadershipRapid international expansion shifts revenue away from a challenged Canadian market into higher-margin, regulated markets. Leadership positions in Germany, Poland and Australia create durable customer and distribution advantages and diversify regulatory and demand risk long-term.
EU‑GMP Capacity And Genetics-driven Production AdvantagesAn accretive EU‑GMP facility expands export-ready manufacturing capacity while genetics-driven yield gains materially lower unit costs. Together these structural operational improvements support sustainable margin expansion and scalable supply for international tenders and contracts.
Bears Say
Negative Free Cash FlowRecent FCF outflows show the business is not yet self-funding. Persistent negative cash generation can erode liquidity buffers over time, force external financing, and constrain reinvestment in production scale or marketing until consistent positive free cash flow is re-established.
Weak And Volatile ProfitabilityDeclining top-line and recurring operating losses indicate unstable earnings power. Volatility (from small profit to large loss) increases execution risk and undermines the durability of margins and long-term return on invested capital until revenue growth and cost structure prove sustainable.
Canadian Reimbursement Cut And Reduced Domestic DiversificationA structural 30% cut to Canadian medical reimbursement materially reduces domestic margins and cash flow. Concurrently exiting the Canadian consumer segment narrows revenue diversity, increasing reliance on international execution; both heighten downside if international demand or pricing softens.
Aurora Cannabis News
21P FAQ
What was Aurora Cannabis’s price range in the past 12 months?
Aurora Cannabis lowest stock price was €2.22 and its highest was €5.62 in the past 12 months.
What is Aurora Cannabis’s market cap?
Aurora Cannabis’s market cap is €162.64M.
When is Aurora Cannabis’s upcoming earnings report date?
Aurora Cannabis’s upcoming earnings report date is Nov 11, 2026 which is in 91 days.
How were Aurora Cannabis’s earnings last quarter?
Aurora Cannabis released its earnings results on Aug 05, 2026. The company reported -€0.044 earnings per share for the quarter, beating the consensus estimate of -€0.114 by €0.07.
Is Aurora Cannabis overvalued?
According to Wall Street analysts Aurora Cannabis’s price is currently Undervalued.
Does Aurora Cannabis pay dividends?
Aurora Cannabis does not currently pay dividends.
What is Aurora Cannabis’s EPS estimate?
Aurora Cannabis’s EPS estimate is -0.04.
How many shares outstanding does Aurora Cannabis have?
Aurora Cannabis has 64,861,820 shares outstanding.
What happened to Aurora Cannabis’s price movement after its last earnings report?
Aurora Cannabis reported an EPS of -€0.044 in its last earnings report, beating expectations of -€0.114. Following the earnings report the stock price went down -1.637%.
Which hedge fund is a major shareholder of Aurora Cannabis?
Currently, no hedge funds are holding shares in DE:21P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.64 (53.50% Upside)
€3.64 (53.50% Upside)
Blogger Sentiment
Bullish
DE:21P Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth €41.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.73%
Trailing 12-Months
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
21P Company Deck
21P Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.View all DE:21P earnings summaries21P Stock 12 Month Forecast
Average Price Target
€3.64
▲(53.50% Upside)